Scinai Immunotherapeutics doubles CDMO revenue, but can the Recipharm deal change the bigger picture?
Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.
What the PinCell acquisition option reveals about Scinai Immunotherapeutics’ pipeline strategy
Scinai Immunotherapeutics seeks €12M EU funding to advance PC111 for rare autoimmune skin diseases. Explore the clinical, regulatory, and industry implications.